Please ensure Javascript is enabled for purposes of website accessibility

Why Vaxart Shares Popped 78% in April

By Jason Hawthorne - May 4, 2021 at 9:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shareholders keep getting their hopes up for the company's tablet-based COVID-19 vaccine.

What happened?

Vaxart (VXRT 1.15%), the biotech creating tablet-based vaccines, jumped 78.2% last month according to S&P Global Market Intelligence. The increase recovered some of the ground it lost after Phase 1 data from its COVID-19 vaccine disappointed investors in early February. Shares closed the month at $10.78.

A person holding a glass of water in one hand and a pill in the other.

Image source: Getty Images.

So what?

About three months ago, investors bid shares of Vaxart higher in anticipation of results that it failed to deliver. The company kicked off May by reporting disappointing earnings before the bell on Monday May 3. That triggered a sell-off that erased much of April's gains. Despite the share volatility, the company plows forward.

Now what?

Management announced it will advance its VXA-CoV2-1 tablet vaccine into Phase 2. The company also plans to advance its norovirus vaccine through studies of a booster dose and in the elderly population.

Vaxart continues to trade on its potential. However, that potential coming to fruition is important for the U.S. to beat the pandemic. The company's own study suggested 19 million vaccine-skeptical Americans -- many in underserved demographics -- would get inoculated if the method of administration was pill rather than injection.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$3.52 (1.15%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.